查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1675295

2025 年至 2033 年罕見血液疾病治療市場報告（按療法、疾病適應症、配銷通路和地區分類）

Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy, Disease Indication, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球獲得性孤兒血液疾病治療市場規模達到 95 億美元。罕見血液疾病診斷率的上升、基因治療和生物製劑的進步、政府透過孤兒藥指定和監管激勵措施提供的支持不斷增加、人們對這些疾病的認知不斷提高以及治療效果的提高是推動市場成長的一些主要因素。

後天性孤兒血病是一種罕見的血液疾病，因無法產生紅血球 (RBC) 或血液中紅血球不足而引起。它們包括多種疾病，例如骨髓增生異常綜合症 (MDS)、特發性血小板減少性紫斑症 (ITP)、陣發性睡眠性血紅蛋白尿 (PNH)、骨髓纖維化 (MF)、真性紅血球增多症 (PV) 和後天性粒細胞缺乏症。它們會導致骨髓功能異常並減少血小板數量。由於它們可以透過重組因子、免疫球蛋白輸注療法、活化凝血酶原複合物濃縮物和血小板生成素受體激動劑等多種療法進行治療，因此全球對獲得性孤兒血液疾病治療藥物的需求正在上升。

後天性孤兒血液疾病治療市場趨勢：

目前，大眾對血液疾病及其治療方案認知的不斷提高，以及全球個人收入水準的不斷提高，是積極影響市場的主要因素之一。此外，由於老年人口的增加，對血液疾病治療選擇的需求不斷增加，這也促進了市場的成長。與此相符的是，各國的管理機構和私人組織正在透過在個人中傳播有關血液相關疾病發生的認知來鼓勵採用血液疾病治療方法，並在世界各地提供多項醫療保健舉措，推動市場的成長。除此之外，由於全球各種血液相關疾病的發生率不斷上升，血液疾病治療的採用也日益廣泛，這為市場帶來了積極的前景。此外，透過世界各地的線上和線下藥局廣泛供應的孤兒血液疾病治療藥物也促進了市場的成長。除此之外，個人對個人化醫療的需求不斷成長，以及全球醫療保健基礎設施的改善，為行業投資者提供了豐厚的成長機會。除此之外，全球個人對具有成本效益和高品質護理解決方案的需求也在增加。再加上人們擴大採用預防性護理和保健服務以避免個人之間疾病的廣泛傳播，這些都促進了市場的成長。此外，主要製造商正在為患有鐮狀細胞性貧血的兒科患者引入基於羥基脲的治療方法，這支持了市場的成長。

本報告回答的關鍵問題：

  • 全球獲得性孤兒血液疾病治療市場迄今表現如何？
  • 全球獲得性孤兒血液疾病治療市場的促進因素、限制因素和機會有哪些？
  • 每個促進因素、限制因素和機會對全球獲得性孤兒血液疾病治療市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家擁有最具吸引力的後天孤兒血液疾病治療市場？
  • 根據治療方法，市場區隔如何？
  • 在獲得性孤兒血液疾病治療市場中哪種療法最具吸引力？
  • 根據疾病指徵，市場如何分類？
  • 在後天性孤兒血液疾病治療市場中，哪種疾病適應症最具吸引力？
  • 根據配銷通路，市場如何分類？
  • 在獲得性孤兒血液疾病治療市場中，哪個配銷通路最具吸引力？
  • 市場的競爭格局是怎麼樣的？
  • 全球獲得性孤兒血液疾病治療市場的主要參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球獲得性孤兒血液疾病治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依療法

  • 重組因子
  • 免疫球蛋白輸注治療
  • 活性凝血酶原複合物濃縮物
  • 血小板生成素受體激動劑
  • 其他

第7章：市場區隔：依疾病適應症

  • 後天性粒細胞缺乏症
  • 後天性血友病
  • 後天性血管性血友病症候群
  • 陣發性睡眠性血紅素尿症 (PNH)
  • 骨髓造血不良症候群
  • 其他

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 10 章：促進因素、限制因素與機遇

  • 概述
  • 驅動程式
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Alexion Pharmaceuticals Inc. (AstraZeneca plc)
    • Amgen Inc.
    • GSK plc
    • Novartis AG
    • Novo Nordisk A/S
    • Otsuka Pharmaceutical Co. Ltd.
    • Rigel Pharmaceuticals Inc.
    • Roche Holding AG
    • Sanofi
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A8217

The global acquired orphan blood diseases therapeutics market size reached USD 9.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.1 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The increasing diagnosis rates of rare blood disorders, advancements in gene therapy and biologics, growing government support through orphan drug designations and regulatory incentives, the rising awareness of these conditions, and improvements in treatment efficacy are some of the major factors propelling the market growth.

Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.

Acquired Orphan Blood Diseases Therapeutics Market Trends:

At present, the increasing awareness about blood diseases and their treatment options among the masses, along with the inflating income level of individuals worldwide, represents one of the major factors influencing the market positively. Moreover, the rising demand for blood disease therapeutics options due to the increasing geriatric population is strengthening the growth of the market. In line with this, governing agencies and private organizations of various countries are encouraging the adoption of blood disease therapeutics by spreading awareness about the occurrence of blood-associated disorders among individuals and offering several healthcare initiatives around the world is impelling the growth of the market. Apart from this, the growing adoption of blood disease therapeutics due to the increasing prevalence of various blood-related disorders among individuals across the globe is offering a positive market outlook. Additionally, the wide availability of acquired orphan blood disease therapeutics drugs through online and offline pharmacy stores around the world is contributing to the growth of the market. Besides this, the increasing demand for personalized medicines among individuals, along with the improving healthcare infrastructure worldwide, is offering lucrative growth opportunities to industry investors. In addition to this, there is a rise in the demand for cost-effective and quality care solutions among individuals across the globe. This, coupled with the increasing adoption of preventative care and wellness services to avoid widespread disease among individuals, is bolstering the growth of the market. Furthermore, key manufacturers are introducing hydroxyurea-based treatment for pediatric patients with sickle cell anemia, which is supporting the growth of the market.

Key Market Segmentation:

Therapy Insights:

  • Recombinant Factor
  • Immunoglobulin Infusion Therapy
  • Activated Prothrombin Complex Concentrate
  • Thrombopoietin Receptor Agonists
  • Others

Disease Indication Insights:

  • Acquired Agranulocytosis
  • Acquired Hemophilia
  • Acquired Von Willebrand Syndrome
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Myelodysplastic Syndrome
  • Others

Distribution Channel Insights:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics. Some of the factors driving the North America acquired orphan blood diseases therapeutics market included the growing awareness about several treatment options, wide availability of therapeutic drugs, favorable government initiatives, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global acquired orphan blood diseases therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the disease indication?
  • Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acquired Orphan Blood Diseases Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Recombinant Factor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunoglobulin Infusion Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Activated Prothrombin Complex Concentrate
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Thrombopoietin Receptor Agonists
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Disease Indication

  • 7.1 Acquired Agranulocytosis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Acquired Hemophilia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Acquired Von Willebrand Syndrome
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Myelodysplastic Syndrome
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alexion Pharmaceuticals Inc. (AstraZeneca plc)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Novo Nordisk A/S
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Otsuka Pharmaceutical Co. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Rigel Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Roche Holding AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Sanofi
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Therapy (in %), 2024
  • Figure 5: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Disease Indication (in %), 2024
  • Figure 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: North America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: North America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: United States: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: United States: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Canada: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Canada: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: China: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: China: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Japan: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Japan: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: India: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: India: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: South Korea: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: South Korea: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Australia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Australia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Europe: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Germany: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Germany: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: France: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: France: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Italy: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Italy: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Spain: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Spain: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Russia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Russia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Latin America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Latin America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Brazil: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Brazil: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Mexico: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Mexico: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 84: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 86: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Value Chain Analysis
  • Figure 87: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Disease Indication (in Million USD), 2025-2033
  • Table 4: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Competitive Structure